多西紫杉醇联合卡培他滨治疗晚期胃癌的疗效观察

Efficacy and safety of docetaxel combined with capecitabine for the treatment of advanced gastric cancer

目的:观察多西紫杉醇联合卡培他滨治疗晚期胃癌的临床疗效及不良反应。方法:31例晚期胃癌患者采用多西紫杉醇75 mg·m^(-2)静脉滴注d1;卡培他滨2 000 mg·m^(-2)·d^(-1),分2次口服。d1～14,21d为1个周期,连用2个周期后评价疗效。结果:全组31例均可评价疗效,每例进行2～4个周期的治疗,共完成90个周期。其中获得CR 0例,PR14例(45．2％),SD12例(38．7％),PD5例(16．1％),总有效率(RR)45．2％(14/31)。中位疾病进展时间(TTP)为5．3个月,中位生存期(OS)为8．9个月。临床受益者共22例(71．0％);主要不良反应为骨髓抑制、手足综合征和外周神经损害,其他不良反应可耐受,经积极对症治疗后好转。结论:多西紫杉醇联合卡培他滨治疗晚期胃癌有较好的疗效,毒副反应可以耐受,值得深入研究。

Objective： To assess the efficacy and safety of docetaxel combined with capecitabin for the treatment of advanced gastric cancer. Methods： Thirty-one patients with advanced gastric cancer received a regimen of docetaxel （75 mg· m^-2, ivgtt once on day 1 ） and capecitabine （ 1 000 mg·m^-2. d^-1, po, twice daily on dayl to 14）. The regimen was repeated every 21 days. Results：Thirty-one patients received 2 to 4 cycles of chemotherapy, totally 90 cycles. The overall response rate was 45.2% （ CR 0, PR 14, SD 12 and PD 5 cases）. The median time to progression was 5.3 months. The median overall survival time was 8.9 months. Twenty-two patients benefited from the regimen. The main adverse events were myelosuppression, hand-foot syndrome and peripheral neuritis. Conclusion： Combination of docetaxel and capecitabine is effective and better tolerated for advanced gastric cancer.